A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
At a glance
- Drugs Ramucirumab (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 18 May 2017 Planned End Date changed from 1 Oct 2018 to 1 Jan 2019.
- 18 May 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.
- 12 Dec 2016 Planned End Date changed from 1 May 2017 to 1 Oct 2018.